Art. -Nr.: HY-124955

proTAME

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

proTAME, a cell-permeable proagent form of TAME, is an anaphase promoting complex/cyclosome (APC/C) inhibitor. proTAME causes cell cycle arrest in metaphase.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 97.33%
CAS. Nr.: 1362911-19-0
Formel: C₃₄H₃₈N₄O₁₂S
Molecular Weight:726.75

Speicherung:

Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

proTAME Chemical Structure

CAS. Nr.: 1362911-19-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

proTAME, a cell-permeable proagent form of TAME, is an anaphase promoting complex/cyclosome (APC/C) inhibitor. proTAME causes cell cycle arrest in metaphase^[1]^[2].

In Vitro

ProTAME prevents anaphase entry in mouse and bovine oocytes and also in mouse 2-cell embryos. proTAME (0-100 μM ) treatment shows dose-dependent metaphase arrest in mammalian oocytes and early cleavage embryos. And the metaphase arrest induced by this drug does not require spindle assembly checkpoint (SAC) activity^[1].
ProTAME arrest of meiosis I in mouse oocytes is due to the inhibition of APC/C. In contrast to the somatic cells, the arrest in oocytes and embryos is not reversible^[1].
proTAME (0-20 μM) dose-dependently affects morphological parameters of the spindle in oocytes and in embryos^[1].
proTAME is efficient in overcoming resistance caused by the hyperphosphorylation of CDH1 in glioblastoma cells, polo-like kinase 1 (PLK1)-based drug resistance in ovarian cancer cells and CDC20-based resistance in diffuse large B-cell lymphoma^[1].
proTAME inhibits OVCAR-3 cells growth with an IC₅₀ of 12.5 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1362911-19-0
Appearance Oil
Molecular Weight 726.75
Formel C₃₄H₃₈N₄O₁₂S
Color White to off-white
SMILES

O=C(CC1=CC=CC=C1)OCOC(N/C(NC(OCOC(CC2=CC=CC=C2)=O)=O)=N/CCC[C@@H](C(OC)=O)NS(=O)(C3=CC=C(C=C3)C)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (7)

All IFWBCell Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nature

CDK5-cyclin B1 regulates mitotic fidelity. [Abstract]

2024 Sep;633(8031):932-940. PMID: 39232161

proTAME purchased from MedChemExpress. Usage Cited in: Nature. 2024 Sep;633(8031):932-940. [Abstract]

Representative images of RPE-1 CDK5-as cells treated as indicated, released from RO-3306 into media containing 20μM proTAME for 2 hours and stained with α-tubulin and DAPI (upper panel). Metaphase plate width and spindle length measurements for these representative cells are shown in the table on the right. Quantification of metaphase plate width and spindle length following indicated treatments (lower panel).
Science

Live chromosome identifying and tracking reveals size-based spatial pathway of meiotic errors in oocytes. [Abstract]

2024 Jul 19;385(6706):eadn5529. PMID: 39024439

proTAME purchased from MedChemExpress. Usage Cited in: Science. 2024 Jul 19;385(6706):eadn5529. [Abstract]

Preventing internal positioning reduces the risk of premature chromosome separation. 3D-reconstructed images of chromosomes (H2B-SNAP, white), NDC80-NUF2 beads (NDC80-sfGFP, green), and prematurely separated chromosomes (magenta) in proTAME (2.5 μM)-treated aged oocytes. Oocytes were monitored for premature chromosome separation by live imaging for 37 hours. In the plot, each spot corresponds to the data from one experiment. Bars indicate the percentage of oocytes that exhibited premature chromosome separation in four independent experiments. The number of oocytes is shown in parentheses. scale bars, 5 μm (for magnified images, 1.5 μm).
Science

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. [Abstract]

2024 Jun 7;384(6700):eadk0775. PMID: 38843331

proTAME purchased from MedChemExpress. Usage Cited in: Science. 2024 Jun 7;384(6700):eadk0775. [Abstract]

Immunoblot analysis of APC/C target proteins securin and cyclin B1 as well as ERK activity readouts pERK and pRSK following treatment with proTAME (APC/Ci) (5-10 μM; 24 h) and/or ERKi in Pa16C cells. The results showed that proTAME was verified to prevent the reduction in protein levels of securin and cyclin B1 caused by 24-hour treatment with ERKi.
Nat Commun

CENP-F-dependent DRP1 function regulates APC/C activity during oocyte meiosis I. [Abstract]

2022 Dec 13;13(1):7732. PMID: 36513638
Cell Death Dis

Metabolomic profiling delineates the role of adenosine in oocyte quality and embryonic development. [Abstract]

2026 Jun 9. PMID: 42265076
Sci China Life Sci

Mutual regulation between cell cycle and transcription termination factor TTF2. [Abstract]

2025 Aug;68(8):2348-2362. PMID: 40410652

proTAME purchased from MedChemExpress. Usage Cited in: Sci China Life Sci. 2025 Aug;68(8):2348-2362. [Abstract]

Cells treated with proTAME (10 μM; 3-12 h) were collected at the indicated times and detected with immunoblotting.
FASEB J

DeSUMOylating isopeptidase 1 participates in the faithful chromosome segregation and vincristine sensitivity. [Abstract]

2024 Dec 13;38(24):e70261. PMID: 39698932

proTAME purchased from MedChemExpress. Usage Cited in: FASEB J. 2024 Dec 13;38(24):e70261. [Abstract]

HeLa S3 cells were treated with siDESI1 #1. After 24 h, cells were incubated with 1.5 nM VCR, 5 μM proTAME, or their combination for a duration of 3 days, and a CCK‐8 assay was performed. The absorbance ratio is expressed relative to control cells (siCtrl, DMSO).

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (137.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3760 mL

6.8799 mL

13.7599 mL

5 mM

0.2752 mL

1.3760 mL

2.7520 mL

10 mM

0.1376 mL

0.6880 mL

1.3760 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (3.44 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lenka Radonova, et al. ProTAME Arrest in Mammalian Oocytes and Embryos Does Not Require Spindle Assembly Checkpoint Activity. Int J Mol Sci. 2019 Sep 13;20(18):4537. [Content Brief]

[2]. Monika Raab, et al. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. Neoplasia. 2019 Apr;21(4):363-375. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3760 mL	6.8799 mL	13.7599 mL	34.3997 mL
	5 mM	0.2752 mL	1.3760 mL	2.7520 mL	6.8799 mL
	10 mM	0.1376 mL	0.6880 mL	1.3760 mL	3.4400 mL
	15 mM	0.0917 mL	0.4587 mL	0.9173 mL	2.2933 mL
	20 mM	0.0688 mL	0.3440 mL	0.6880 mL	1.7200 mL
	25 mM	0.0550 mL	0.2752 mL	0.5504 mL	1.3760 mL
	30 mM	0.0459 mL	0.2293 mL	0.4587 mL	1.1467 mL
	40 mM	0.0344 mL	0.1720 mL	0.3440 mL	0.8600 mL
	50 mM	0.0275 mL	0.1376 mL	0.2752 mL	0.6880 mL
	60 mM	0.0229 mL	0.1147 mL	0.2293 mL	0.5733 mL
	80 mM	0.0172 mL	0.0860 mL	0.1720 mL	0.4300 mL
	100 mM	0.0138 mL	0.0688 mL	0.1376 mL	0.3440 mL

Keywords

proTAME

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

proTAME

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) proTAME

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

proTAME

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) proTAME

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

proTAME Related Classifications

HY-124955 Related Classifications